He will be replaced by Mary Schramke, Lynx's vice president of product development, who will become acting CEO on Dec. 15. She will lead the company as it proceeds with its merger with Solexa. Schramke holds a PhD in microbiology from
Corcoran spent nine years at Lynx, working in various managerial positions, and was responsible for the company's short read DNA sequencing technology.
Lynx and Solexa are scheduled to merge during the first quarter of 2005. The companies had originally planned to tie the knot during the fourth quarer of 2004.
Read the following most-recent GenomeWeb News articles about Lynx and its impending merger with Solexa: